Gondola Medical Technologies | New research momentum
Share this article
Building clinical research momentum with 500’000 CHF Tech Growth loan
Clinical research and studies demonstrate Gondola Medical Technologies AMPS therapy’s effectiveness for people with neurological disease to move better and live better. The CHF 500’000 Tech Growth loan from the Fondation pour l’Innovation Technologique (FIT), supports Gondola Medical Technologies to develop their clinical research capabilities further.
From start-up to scale-up
Gondola Medical Technologies is a Swiss MedTech company based at Biopôle in the Canton of Vaud, currently employing 16 people. Founded in 2011, Gondola celebrates its ten-year anniversary in 2021. Establishing a complementary side-effects-free and non-invasive treatment form comes with its challenges and takes time to mature. In 2014 it was awarded the StartCup price as the most innovative company in Ticino. Since 2019 it raised a total of 4 million Euro (equity and loans), including a 2.5 million Euro grant from the EU Horizon 2020 research and innovation program, and a first installment of CHF 200’000 from the Fondation pour l’Innovation Technologique (FIT).
Backed by science: clinical expertise and research
The claim backed by science demonstrates Gondola Medical Technologies’ commitment to scientific rigor. The raised funds of CHF 500’000 Tech Growth loan from FIT come in two installments, CHF 200’000 upfront and CHF 300’000 based on a milestone plan submitted to FIT’s Selection Committee. Gondola Medical Technologies dedicates these funds to research and development, which includes growing their clinical research team and studies.
Fondation pour l’Innovation Technologique (FIT)
The FIT founded in the canton of Vaud in 1994, is a non-profit organisation that encourages entrepreneurship, supports innovation, and contributes to boosting the local economy by granting loans and grants to young companies. The funding is targeted at start-ups in Vaud and French-speaking Switzerland, innovating either through their technological content or their business model.